3.11.1 Antifibrotics |
RED Pirfenidone capsules 267mg |
For the treatment of idiopathic pulmonary fibrosis recommended as an option by NICE TA504 in adults only if: |
> the person has a forced vital capacity (FVC) between 50% and 80% predicted |
> the company [provides pirfenidone with the agreed discount agreed in the patient access scheme and |
> treatment is stopped if there is evidence of disease progression (an absolute decline of 10% or more in predicted |
FVC within any 12-month period). |
|
NICE TAG379 Nintendanib (FVC between 50% and 80% predicted) |
RED Nintedanib capsules 100mg, 150mg |
For the treatment of idiopathic pulmonary fibrosis in people with a forced vital capacity (NICE TAG379) |
between 50% and 80% predicted recommend as an option by NICE. |
|
NICE TA864 Nintedanib (forced vital capacity above 80% predicted) |
RED Nintedanib (Ofev®) |
Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis in adults, only if: |
> they have a forced vital capacity of above 80% predicted |
> the company provides it according to the commercial arrangement. |
NHS England Commissioned |
RED Nintedanib (Ovef®) |
NICE TA747 Recommended, within its marketing authorisation, as an option for treating chronic progressive fibrosing |
interstitial lung diseases (PF‑ILD) in adults. |
NHS England Commissioned |